NO331599B1 - Anvendelse av gemiflokasasin eller et salt derav og et karbapenem antibakterielt middel for fremstilling av et medikament til behandling av bakterielle infeksjoner, og sett inneholdende det samme - Google Patents

Anvendelse av gemiflokasasin eller et salt derav og et karbapenem antibakterielt middel for fremstilling av et medikament til behandling av bakterielle infeksjoner, og sett inneholdende det samme Download PDF

Info

Publication number: NO331599B1
Authority: NO; Norway
Prior art keywords: gemifloxacin; salt; antibacterial agent; carbapenem antibacterial; carbapenem
Prior art date: 2001-11-30

Application number

NO20042660A

Other languages

English (en)

Norwegian (no)

Other versions

NO20042660L (no

Inventor

Nancy Niconovich

Stephen Rittenhouse

Lynn Mccloskey

Kyong-Sook Pack

Mu-Yong Kim

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2004-06-24

Publication date

2012-02-06

2004-06-24 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2004-06-24 Publication of NO20042660L publication Critical patent/NO20042660L/no

2012-02-06 Publication of NO331599B1 publication Critical patent/NO331599B1/no

Links

YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title claims abstract description 42
150000003839 salts Chemical class 0.000 title claims abstract description 37
208000035143 Bacterial infection Diseases 0.000 title claims abstract description 10
208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 10
239000003242 anti bacterial agent Substances 0.000 title claims description 41
239000003814 drug Substances 0.000 title claims description 20
238000011282 treatment Methods 0.000 title claims description 12
238000004519 manufacturing process Methods 0.000 title claims 2
ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims abstract description 57
229960003170 gemifloxacin Drugs 0.000 claims abstract description 57
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 25
229960002260 meropenem Drugs 0.000 claims description 12
238000009472 formulation Methods 0.000 claims description 11
WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 10
229960002182 imipenem Drugs 0.000 claims description 10
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
238000011260 co-administration Methods 0.000 claims description 2
JIYMVSQRGZEYAX-CWUUNJJBSA-N gemifloxacin mesylate Chemical compound CS(O)(=O)=O.C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 JIYMVSQRGZEYAX-CWUUNJJBSA-N 0.000 claims description 2
229960001151 gemifloxacin mesylate Drugs 0.000 claims description 2
DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical group C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 2
ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 11
241000894006 Bacteria Species 0.000 description 18
229940079593 drug Drugs 0.000 description 17
229940088710 antibiotic agent Drugs 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
CTUAQTBUVLKNDJ-OBZXMJSBSA-N meropenem trihydrate Chemical compound O.O.O.C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 CTUAQTBUVLKNDJ-OBZXMJSBSA-N 0.000 description 10
GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
230000003115 biocidal effect Effects 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000000654 additive Substances 0.000 description 5
230000000996 additive effect Effects 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000124008 Mammalia Species 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
206010021703 Indifference Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
206010048038 Wound infection Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
229940126575 aminoglycoside Drugs 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
JFUIHGAGFMFNRD-UHFFFAOYSA-N fica Chemical group FC1=CC=C2NC(C(=O)NCCS)=CC2=C1 JFUIHGAGFMFNRD-UHFFFAOYSA-N 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000010445 mica Substances 0.000 description 2
229910052618 mica group Inorganic materials 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000006150 trypticase soy agar Substances 0.000 description 2
230000002792 vascular Effects 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
SNLMOXFUCILIPL-UHFFFAOYSA-N 1,8-naphthyridine-2-carboxylic acid Chemical class C1=CC=NC2=NC(C(=O)O)=CC=C21 SNLMOXFUCILIPL-UHFFFAOYSA-N 0.000 description 1
NLEPLDKPYLYCSY-UHFFFAOYSA-N 2-fluoroquinoline Chemical compound C1=CC=CC2=NC(F)=CC=C21 NLEPLDKPYLYCSY-UHFFFAOYSA-N 0.000 description 1
108010041052 DNA Topoisomerase IV Proteins 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000588621 Moraxella Species 0.000 description 1
TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
241000588767 Proteus vulgaris Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241001147691 Staphylococcus saprophyticus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000012080 ambient air Substances 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000037358 bacterial metabolism Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
238000003287 bathing Methods 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
229960003169 biapenem Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000003115 checkerboard titration Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
229940032049 enterococcus faecalis Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
238000013100 final test Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229950011346 panipenem Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
231100000316 potential neurotoxicity Toxicity 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940007042 proteus vulgaris Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20042660A 2001-11-30 2004-06-24 Anvendelse av gemiflokasasin eller et salt derav og et karbapenem antibakterielt middel for fremstilling av et medikament til behandling av bakterielle infeksjoner, og sett inneholdende det samme NO331599B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33513101P	2001-11-30	2001-11-30
PCT/KR2002/002247 WO2003045389A1 (en)	2001-11-30	2002-11-29	A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent

Publications (2)

Publication Number	Publication Date
NO20042660L NO20042660L (no)	2004-06-24
NO331599B1 true NO331599B1 (no)	2012-02-06

Family

ID=23310394

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042660A NO331599B1 (no)	2001-11-30	2004-06-24	Anvendelse av gemiflokasasin eller et salt derav og et karbapenem antibakterielt middel for fremstilling av et medikament til behandling av bakterielle infeksjoner, og sett inneholdende det samme

Country Status (13)

Country	Link
US (1)	US20050020567A1 (de)
EP (1)	EP1458390B1 (de)
AT (1)	ATE404197T1 (de)
AU (1)	AU2002360216A1 (de)
CA (1)	CA2468033C (de)
CY (1)	CY1108472T1 (de)
DE (1)	DE60228324D1 (de)
DK (1)	DK1458390T3 (de)
ES (1)	ES2312654T3 (de)
MX (1)	MXPA04005178A (de)
NO (1)	NO331599B1 (de)
PT (1)	PT1458390E (de)
WO (1)	WO2003045389A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006040893A1 (ja) *	2004-10-08	2006-04-20	Dainippon Sumitomo Pharma Co., Ltd.	新規な抗菌性医薬
US9292565B2 (en) *	2010-06-30	2016-03-22	International Business Machines Corporation	Template-based recognition of food product information

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080757A (en) *	1996-06-06	2000-06-27	Pfizer Inc	Antibiotic quinolones and derivatives
WO2001095876A1 (en) *	2000-06-09	2001-12-20	Baylor College Of Medicine	The combination of antimicrobial agents and bacterial interference to coat medical devices

2002
- 2002-11-29 CA CA002468033A patent/CA2468033C/en not_active Expired - Fee Related
- 2002-11-29 US US10/496,803 patent/US20050020567A1/en not_active Abandoned
- 2002-11-29 AU AU2002360216A patent/AU2002360216A1/en not_active Abandoned
- 2002-11-29 EP EP02795443A patent/EP1458390B1/de not_active Expired - Lifetime
- 2002-11-29 DK DK02795443T patent/DK1458390T3/da active
- 2002-11-29 ES ES02795443T patent/ES2312654T3/es not_active Expired - Lifetime
- 2002-11-29 PT PT02795443T patent/PT1458390E/pt unknown
- 2002-11-29 DE DE60228324T patent/DE60228324D1/de not_active Expired - Lifetime
- 2002-11-29 WO PCT/KR2002/002247 patent/WO2003045389A1/en not_active Ceased
- 2002-11-29 AT AT02795443T patent/ATE404197T1/de active
- 2002-11-29 MX MXPA04005178A patent/MXPA04005178A/es active IP Right Grant
2004
- 2004-06-24 NO NO20042660A patent/NO331599B1/no not_active IP Right Cessation
2008
- 2008-10-31 CY CY20081101239T patent/CY1108472T1/el unknown

Also Published As

Publication number	Publication date
EP1458390A1 (de)	2004-09-22
CA2468033A1 (en)	2003-06-05
AU2002360216A1 (en)	2003-06-10
EP1458390A4 (de)	2007-07-04
PT1458390E (pt)	2008-10-02
ATE404197T1 (de)	2008-08-15
EP1458390B1 (de)	2008-08-13
DE60228324D1 (de)	2008-09-25
ES2312654T3 (es)	2009-03-01
US20050020567A1 (en)	2005-01-27
MXPA04005178A (es)	2004-08-11
WO2003045389A1 (en)	2003-06-05
DK1458390T3 (da)	2008-12-15
CY1108472T1 (el)	2014-04-09
CA2468033C (en)	2008-02-12
NO20042660L (no)	2004-06-24

Legal Events

Date	Code	Title	Description
2015-06-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6340689B1 (en)	2002-01-22	Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
Minardi et al.	2012	Efficacy of tigecycline and rifampin alone and in combination against Enterococcus faecalis biofilm infection in a rat model of ureteral stent
US20250170106A1 (en)	2025-05-29	Use of su3327 in preparation of medicament for enhancing efficacy of polymyxin against bacterial infection
ES2299430T3 (es)	2008-06-01	Utilizacion de compuestos de gemifloxacina contra bacterias.
US6262071B1 (en)	2001-07-17	Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
Fantin et al.	1993	Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus
WO2006010147A2 (en)	2006-01-26	Control of biofilm formation
US7169792B2 (en)	2007-01-30	Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic
CA2468033C (en)	2008-02-12	A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
Roujansky et al.	2025	Pathophysiology and prevention of ventriculostomy-related infections: a review
Contrepois et al.	1986	Kinetics and bactericidal effect of gentamicin and latamoxef (moxalactam) in experimental Escherichia coli endocarditis
US7595328B2 (en)	2009-09-29	Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
US20060264411A1 (en)	2006-11-23	Control of biofilm formation
WO1993014770A1 (en)	1993-08-05	Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivative
CA2281817C (en)	2008-07-29	Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
JP2001097891A (ja)	2001-04-10	呼吸器系病原菌に対するフルオロキノロン化合物の使用法
US20040023983A1 (en)	2004-02-05	Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
US10398664B2 (en)	2019-09-03	Methods of diagnosing and treating infected implants
Steer et al.	1997	In-vitro modelling of the bactericidal activity of teicoplanin versus flucloxacillin as used in surgical prophylaxis, against Staphylococcus aureus.
KR20030060928A (ko)	2003-07-16	병원성 헬리코박터 박테리아에 대한 플루오로퀴놀론화합물의 사용방법
JP2001097863A (ja)	2001-04-10	嫌気性病原菌に対するフルオロキノロン化合物の使用法
HK40053249A (en)	2022-02-04	Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof
Shales	2012	Surgical wound infection and antimicrobial prophylaxis
ZA200300903B (en)	2003-11-10	Combinations of dalfopristine/quinupristine with cefpirome.